AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00637585
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00252278
Drug: atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02034916
Drug: talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00203216
Drug: levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
Trial: NCT00729560
Drug: Flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg twice daily for 4 weeks
Trial: NCT04440085
Drug: Midodrine Hydrochloride
RxNorm normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
Trial: NCT00267657
Drug: Reserpine
RxNorm normalized name: Reserpine
DrugBank: Reserpine (DB00206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03570437
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
Trial: NCT03570437
Drug: Cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg per day
Trial: NCT03570437
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib tablets, 300 mg twice-daily
Trial: NCT00238797
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02010944
Drug: solifenacin succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02010944
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00634075
Drug: omega-3-fatty acids (Omegaven)
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
Trial: NCT00397475
Drug: Colecalciferol
RxNorm normalized name: colecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01972724
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone tablets
Trial: NCT01972724
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin as prescribed in clinical practice
Trial: NCT00536640
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg per os, given daily until tumor progression
Trial: NCT00536640
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
Trial: NCT00536640
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
Trial: NCT00536640
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
Trial: NCT01109498
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral, 2 g/day, day -3 till week 12
Trial: NCT01109498
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 3 mg/kg/day, day -3 till week 12
Trial: NCT01721434
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01265173
Drug: Cefotaxime
RxNorm normalized name: Cefotaxime
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 g
Trial: NCT01265173
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 g
Trial: NCT01265173
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT03960398
Drug: Iatrogenic disease impact on emergency consultations
RxNorm normalized name: IMPACT
DrugBank: Topramezone (DB14826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Determination of the proportion of emergency consultations linked to iatrogenic diseases
Trial: NCT00749749
Drug: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)
RxNorm normalized name: bupivacaine Drug Implant
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
Trial: NCT00002919
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002919
Drug: vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01897259
Drug: Prolotherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
Trial: NCT03598140
Drug: Sildenafil Citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
Trial: NCT02168660
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3, liquid formulation, 5000 IU/mL.
Trial: NCT02047708
Drug: Zibotentan
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective endothelin-A antagonist
Trial: NCT01367483
Drug: IV methylnaltrexone (MNTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01373398
Drug: EO9(Apaziquone)
RxNorm normalized name: Apaziquone
DrugBank: Apaziquone (DB12593)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
Trial: NCT00648349
Drug: Rabeprazole Sodium Delayed-Release Tablets 20 mg
RxNorm normalized name: rabeprazole sodium Delayed Release Oral Tablet
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg, single dose fasting
Trial: NCT00681525
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 80 mg tablet of atorvastatin QD for 10 days
Trial: NCT00681525
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One ezetimibe 10 mg tablet QD for 10 days
Trial: NCT02658240
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Trial: NCT02918279
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered once daily subcutaneously (s.c., under the skin)
Trial: NCT01190007
Drug: Caduet
RxNorm normalized name: Caduet
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
Trial: NCT00098553
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01291615
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
Trial: NCT01291615
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
Trial: NCT00666276
Drug: linezolid (Zyvox)
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration.
Trial: NCT01296191
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop 4 times daily for 3 days and one drop the day of sample collection
Trial: NCT01296191
Drug: besifloxacin
RxNorm normalized name: Besifloxacin
DrugBank: Besifloxacin (DB06771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop 4 times daily for 3 days and one drop on day of sample collection
Trial: NCT01135511
Drug: Sodium Hyaluronate
RxNorm normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ophthalmic topical solution, dosed 6 times/day, 8 weeks
Trial: NCT01641224
Drug: Pinaverium
RxNorm normalized name: pinaverium
DrugBank: Pinaverium (DB09090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
Trial: NCT01641224
Drug: Radix codonopsitis
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radix codonopsitis (\~10-15g)
Trial: NCT04496050
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
Trial: NCT01368016
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
Trial: NCT01368016
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
Trial: NCT01061151
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg twice daily
Trial: NCT01061151
Drug: Nevirapine (NVP): Antepartum Mothers
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg at onset of labor
Trial: NCT01061151
Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail
RxNorm normalized name: emtricitabine / tenofovir disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
Trial: NCT01061151
Drug: Lamivudine-Zidovudine (3TC-ZDV)
RxNorm normalized name: lamivudine / zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/300 mg twice daily
Trial: NCT01061151
Drug: Lopinavir-ritonavir (LPV-RTV)
RxNorm normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
Trial: NCT01641224
Drug: Radix curcumae
RxNorm normalized name: Curcumae Radix (Curcuma Longa)
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radix curcumae (\~10g)
Trial: NCT01061151
Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])
RxNorm normalized name: emtricitabine / tenofovir disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/300 mg
Trial: NCT01061151
Drug: Nevirapine (NVP): Infant short-course
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
Trial: NCT01061151
Drug: Nevirapine (NVP): Infant extended
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
Trial: NCT00964639
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
Trial: NCT00964639
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the surgery infiltration with saline. Thereafter bolus 3 times a day
Trial: NCT02329860
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01684150
Drug: EPZ-5676
RxNorm normalized name: Epzicom
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
Trial: NCT04347434
Drug: Atorvastatin 80mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
Trial: NCT02871791
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02871791
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02871791
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00926562
Drug: Iopromide (Ultravist)
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
Trial: NCT00926562
Drug: Iodixanol (Visipaque)
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
Trial: NCT00534300
Drug: Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
Trial: NCT03151772
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850 mg x 3 taken preoperatively
Trial: NCT00263406
Drug: Administration of an ACE-inhibitor or not
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04135989
Drug: Personalized DAPT duration
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
Trial: NCT01490086
Drug: aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily
Trial: NCT02497053
Drug: pemetrexed/platinum chemotherapy
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Four cycles of pemetrexed/platinum chemotherapy
Trial: NCT02497053
Drug: Pemetrexed/platinum chemotherapy
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Six cycles of pemetrexed/platinum chemotherapy
Trial: NCT02331706
Drug: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03410446
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
Trial: NCT01120418
Drug: Besifloxacin Ophthalmic Suspension 0.6%
DrugBank: Besifloxacin (DB06771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered 3 times a day for 5 days to one eye.
Trial: NCT00338624
Drug: oxybutynin chloride extended release
RxNorm normalized name: oxybutynin chloride Extended Release Oral Tablet
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02878772
Drug: vinpocetine
RxNorm normalized name: Vinpocetine
DrugBank: Vinpocetine (DB12131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
Trial: NCT02878772
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg, once daily, oral medication
Trial: NCT02762123
Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02762123
Drug: BMS-986142 350mg
RxNorm normalized name: BMS dasatinib
DrugBank: BMS-986142 (DB15291)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182999
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
Trial: NCT01619527
Drug: darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
Trial: NCT01619527
Drug: cobicistat
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
Trial: NCT00498368
Drug: Intravenous Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182
Trial: NCT01236001
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03933605
Drug: midazolam and palonosetron group
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
Trial: NCT03933605
Drug: palonosetron group
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
Trial: NCT03149991
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of up to 3mg brexpiprazole
Trial: NCT01895075
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
Trial: NCT03149991
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration 6 times over two weeks of inhaled ketamine